[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"vitamin-d-deficiency\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:vitamin-d-deficiency":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,24,0,[8,50,81,115,153,177,199,225,249,271,294,325,349,382,406,437,461,484,508,527,555,583,615,638],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":31,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":44,"leadSponsor":46,"locationsCount":49},"100644494","phase-4-vitamin-d2-versus-vitamin-d2-plus-calcitriol-in-cholestatic-children-with-vitamin-d-deficiency-100644494",false,"NCT07670611","VITAMIN D2 VERSUS VITAMIN D2 PLUS CALCITRIOL IN CHOLESTATIC CHILDREN WITH VITAMIN D DEFICIENCY","ACCELERATED CORRECTION OF VITAMIN D DEFICIENCY IN CHOLESTATIC CHILDREN: A COMPARATIVE TRIAL OF VITAMIN D2 MONOTHERAPY VERSUS COMBINATION THERAPY WITH CALCITRIOL","VITD-CHOL","Inclusion Criteria:\n\n* Patients younger than 18 years of age.\n* Patients diagnosed with cholestasis, defined as direct\u002Fconjugated bilirubin \\>1 mg\u002FdL for more than 1 month.\n* Patients diagnosed with chronic liver disease.\n* Patients with vitamin D deficiency, defined as serum 25-hydroxyvitamin D (25-OHD) level \\\u003C20 ng\u002FmL, according to the Endocrine Society Clinical Practice Guideline.\n\nExclusion Criteria:\n\n* Pre-existing hypercalciuria, screened by urine calcium testing before enrollment.\n* Patients with benign or malignant tumors.\n* Patients with renal tubular defects, screened by electrolyte testing before enrollment.\n* Patients currently receiving anticonvulsant therapy.\n* Patients who do not attend scheduled follow-up visits.","ALL","18 Years",{"count":20,"type":21},54,"ESTIMATED","INTERVENTIONAL",[24],"PHASE4","The goal of this clinical trial is to learn whether adding calcitriol to vitamin D2 can improve vitamin D deficiency in children with cholestasis and chronic liver disease. Cholestasis is a condition in which bile flow is reduced, which can make it difficult for the body to absorb and process vitamin D. The study will also learn about the safety of using vitamin D2 together with calcitriol.\n\nThe main questions it aims to answer are:\n\n* Does vitamin D2 plus calcitriol increase blood 25-hydroxyvitamin D (25-OHD) levels more than vitamin D2 alone after 3 months of treatment?\n* Does vitamin D2 plus calcitriol help more children reach an adequate vitamin D level by 3 and 6 months?\n* What medical problems, especially high calcium or high phosphorus levels, occur during treatment?\n\nResearchers will compare children who receive vitamin D2 alone with children who receive vitamin D2 plus calcitriol to see which treatment improves vitamin D levels more effectively and safely.\n\nParticipants will:\n\n* Take vitamin D2 alone or vitamin D2 plus calcitriol as assigned by randomization\n* Visit the clinic for study assessments at the start of the study, at 3 months, and at 6 months\n* Have blood tests to measure vitamin D levels, calcium, phosphorus, parathyroid hormone, liver function, and other safety markers\n* Have their treatment reviewed at 3 months; participants whose vitamin D level remains low may have their treatment adjusted according to the study plan\n* Bring back medication packages so researchers can check how regularly the study medicines were taken",[27,28,29,30],"Cholestatic Liver Disease","Chronic Liver Disease (CLD)","Vitamin D Deficiency","Children",[32,33,34,35,36],"cholestasis","pediatrics","vitamin d deficiency","Calcitriol","25-Hydroxyvitamin D2","RECRUITING","2026-06-22",{"date":40,"type":41},"2026-06-26","ACTUAL",{"date":43,"type":41},"2026-04-28",{"date":45,"type":21},"2027-04-20",{"name":47,"class":48},"Chulalongkorn University","OTHER",1,{"id":51,"slug":52,"hasResults":11,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":4,"eligibilityCriteria":56,"healthyVolunteers":57,"sex":17,"minAge":18,"maxAge":58,"enrollmentInfo":59,"targetDuration":4,"studyType":22,"phases":61,"briefSummary":63,"conditions":64,"keywords":67,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":49},"100643649","the-effect-of-vitamin-d-supplementation-on-the-anti-inflammatory-response-in-periodontal-diseases-100643649","NCT07636733","The Effect of Vitamin D Supplementation on the Anti-inflammatory Response in Periodontal Diseases","The Effect of Vitamin D Levels and Supplementation on Anti-inflammatory Response in Periodontal Disease: a Randomized Controlled Clinical Trial","Inclusion Criteria:\n\n* Study groups will be formed according to the 2017 Periodontal Disease Classification. Accordingly:\n* Periodontally healthy; absence of bleeding on probing, erythema, edema, patient symptoms, attachment, and bone loss\n* Gingivitis; patients with an average gingival index ≥0.5 according to Löe and Silness\n* Stage I-II periodontitis; patients with CAL 1-2 or 3-4 mm and a maximum PPD ≤5 mm, showing radiographic horizontal bone loss up to the coronal third of the root (15%-33%), but without tooth loss due to periodontitis\n* Stage III-IV periodontitis; Stage 3 and 4 patients with ≥15 teeth in their mouth, with CAL ≥5 and PPD ≥6 in at least 6 areas, and radiographic bone loss extending to the middle or apical third of the root.\n\nExclusion Criteria:\n\n* Individuals who have undergone periodontal treatment in the last 6 months, have systemic diseases (such as diabetes, parathyroid and thyroid-related endocrine diseases) that may affect periodontal status, patients with chronic liver disease, hypoparathyroidism and renal failure, those who have been using medications that may affect periodontal response (aspirin, non-steroidal anti-inflammatory drugs or steroids) for a long time, those who are using additional vitamin D or calcium supplements in the pre-study phase, those who are pregnant or breastfeeding, and those with hypercalcemia and malabsorption syndrome will not be included in the study.",true,"70 Years",{"count":60,"type":21},120,[62],"NA","A review of the literature revealed that while there are studies investigating the relationship between vitamin D and periodontal disease, there are no studies investigating the anti-inflammatory effect of vitamin D on periodontal disease. Investigators hypothesized that the increased incidence of periodontal disease in individuals with vitamin D deficiency might be due not only to pro-inflammatory effects but also to impaired bone metabolism and a decrease in the anti- inflammatory mechanism. Investigators aimed to determine this by comparing serum and DOS levels of 1,25-dihydroxyvitamin D (1,25(OH)2D), 25-hydroxyvitamin D (25(OH)D3), Receptor activator nuclear kappa B ligand (RANKL), osteoprotegerin (OPG), Tumor Necrosis Factor Related Apoptosis induced Ligand (TRAIL), Developmental endothelial locus (Del)-1, Lipoxin, Resolvin, interleukin (IL)-10, and transforming growth factor-β (TGF-β).\n\nThe study will include 120 individuals who are systemically healthy based on clinical and radiographic examinations and diagnosed with Stage I-II periodontitis, Stage III-IV periodontitis, chronic gingivitis, and periodontally healthy. Periodontal clinical parameters (Probing pocket depth (PPD), Clinical attachment level (CAL), Bleeding on probing (BOP), Plaque index (PI), Gingival index (GI)) will be recorded three times: before treatment, and 6 and 12 weeks after treatment. Gingival crevicular fluid (GCF) and serum samples will be collected from participants at baseline and 12 weeks later for biochemical analysis.",[65,66,29],"Periodontal Diseases","Gingivitis",[68,69,70,71],"periodontitis","gingivitis","Vitamin D","anti-inflammatory","2026-06-08",{"date":74,"type":41},"2026-06-10",{"date":76,"type":41},"2026-06-03",{"date":78,"type":21},"2026-10-16",{"name":80,"class":48},"Recep Tayyip Erdogan University Training and Research Hospital",{"id":82,"slug":83,"hasResults":11,"nctId":84,"briefTitle":85,"officialTitle":86,"acronym":87,"eligibilityCriteria":88,"healthyVolunteers":57,"sex":17,"minAge":89,"maxAge":90,"enrollmentInfo":91,"targetDuration":4,"studyType":92,"phases":4,"briefSummary":93,"conditions":94,"keywords":95,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":105,"lastUpdatePostDateStruct":106,"startDateStruct":108,"completionDateStruct":110,"leadSponsor":112,"locationsCount":49},"100626461","bone-myoregulation-reflex-and-postural-control-in-vitamin-d-deficiency-100626461","NCT07435935","Bone Myoregulation Reflex and Postural Control in Vitamin D Deficiency","Investigation of Postural Stability and Load-Sensitive Neuromuscular Control Mechanisms in Vitamin D Deficiency","BMR-VITD","Inclusion Criteria:\n\n* Age 20 to 40 years.\n* Ability to provide written informed consent.\n* Vitamin D deficiency group: serum 25-hydroxyvitamin D level \\\u003C10 ng\u002FmL measured within the last 3 months (routine clinical testing).\n* Healthy control group: normal vitamin D status based on routine clinical testing within the last 3 months.\n* No use of vitamin D or calcium supplementation within the last 3 months.\n\nExclusion Criteria:\n\n* Known metabolic bone disease other than vitamin D deficiency.\n* Neurological disorder (central or peripheral) or neuromuscular disease.\n* History of lower-limb surgery, fracture, or prosthesis affecting standing balance.\n* Vestibular disorder.\n* BMI \\>30 kg\u002Fm2.\n* Active malignancy.\n* Severe psychiatric disorder.\n* Skin condition preventing placement of surface EMG electrodes.","20 Years","40 Years",{"count":5,"type":21},"OBSERVATIONAL","This observational study aims to investigate the relationship between vitamin D deficiency, postural stability, and neuromuscular control mechanisms in adults. The study will compare individuals with vitamin D deficiency and healthy controls.\n\nParticipants will undergo a single-session evaluation including surface electromyography and postural stability assessments during standing tasks under different loading and vibration conditions. No invasive procedures, medications, or blood sampling will be performed. Previously obtained routine laboratory results will be used for vitamin D status.\n\nThe study is designed to improve understanding of neuromuscular responses associated with vitamin D deficiency and to contribute to future rehabilitation strategies.",[29],[29,96,97,98,99,100,101,102,103,104],"Postural Stability","Balance Control","Neuromuscular Control","Surface Electromyography","Reflex Modulation","Bone Myoregulation Reflex","Standing Balance","Rehabilitation Research","Postural Sway","2026-05-22",{"date":107,"type":41},"2026-05-27",{"date":109,"type":41},"2026-03-05",{"date":111,"type":21},"2026-07-05",{"name":113,"class":114},"Istanbul Physical Medicine Rehabilitation Training and Research Hospital","OTHER_GOV",{"id":116,"slug":117,"hasResults":11,"nctId":118,"briefTitle":119,"officialTitle":120,"acronym":121,"eligibilityCriteria":122,"healthyVolunteers":11,"sex":17,"minAge":123,"maxAge":124,"enrollmentInfo":125,"targetDuration":4,"studyType":92,"phases":4,"briefSummary":127,"conditions":128,"keywords":133,"overallStatus":143,"whyStopped":4,"lastUpdateSubmitDate":144,"lastUpdatePostDateStruct":145,"startDateStruct":147,"completionDateStruct":149,"leadSponsor":151,"locationsCount":49},"100558179","serum-vitamin-d-status-in-critically-ill-children-with-acute-respiratory-infections-100558179","NCT06547749","Serum Vitamin D Status in Critically Ill Children With Acute Respiratory Infections","Assessment of Serum Vitamin D Status and Its Association With Disease Severity and Mortality Risk Among Critically Ill Children With Acute Respiratory Infections: A Cross-Sectional Study","VITD-ARI","Inclusion Criteria:\n\n* Children aged between 1 month and 12 years.\n* Admitted to the PICU with a primary diagnosis of acute respiratory infection.\n* Diagnosis confirmed by clinical symptoms and radiological evidence.\n\nExclusion Criteria:\n\n* Children with known chronic bone diseases or metabolic disorders.\n* Patients receiving vitamin D supplementation prior to admission.\n* Patients with chronic renal or hepatic failure.","1 Month","16 Years",{"count":126,"type":21},63,"Acute respiratory infections (ARIs) are among the leading causes of hospitalization, morbidity, and mortality in children worldwide, particularly among critically ill patients admitted to pediatric intensive care units (PICUs). Vitamin D has an important role not only in bone metabolism but also in regulation of innate and adaptive immune responses, especially within the respiratory tract. Recent evidence suggests that vitamin D deficiency may be associated with increased susceptibility to respiratory infections, greater disease severity, prolonged hospitalization, and higher mortality rates in critically ill children.\n\nThis observational cross-sectional study aims to assess serum vitamin D status among critically ill children admitted to the PICU with acute respiratory infections and to evaluate the relationship between vitamin D levels, severity of respiratory illness, and risk of mortality. The study will include pediatric patients aged 1 month to 16 years admitted to the Pediatric Intensive Care Unit of Assiut University Children's Hospital.\n\nClinical evaluation and laboratory investigations, including serum 25-hydroxyvitamin D levels, serum calcium, and alkaline phosphatase, will be performed within the first 24 hours of admission. Severity of respiratory distress will be assessed using the Pediatric Respiratory Severity Score (PRESS), while mortality risk will be evaluated using the Pediatric Risk of Mortality Score (PRISM III).\n\nThe findings of this study may contribute to better understanding of the role of vitamin D in critically ill children with respiratory infections and may support future strategies for early risk assessment and improved clinical management in pediatric intensive care settings.",[129,130,29,131,132],"Acute Respiratory Infections","Critical Illness in Children","Pediatric Respiratory Infections","Respiratory Distress",[134,70,135,136,137,138,139,140,141,142],"25-hydroxyvitamin D","Pediatric intensive care unit","PICU","Acute respiratory infection","Critically ill children","Pediatric respiratory severity score","Respiratory infection severity","Pediatric critical care","Mortality risk","NOT_YET_RECRUITING","2026-05-05",{"date":146,"type":41},"2026-05-08",{"date":148,"type":21},"2026-06",{"date":150,"type":21},"2027-04",{"name":152,"class":48},"Assiut University",{"id":154,"slug":155,"hasResults":11,"nctId":156,"briefTitle":157,"officialTitle":158,"acronym":4,"eligibilityCriteria":159,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":160,"targetDuration":4,"studyType":22,"phases":162,"briefSummary":164,"conditions":165,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":168,"lastUpdatePostDateStruct":169,"startDateStruct":171,"completionDateStruct":173,"leadSponsor":175,"locationsCount":49},"100414530","phase-2-impact-of-vitamin-d-supplementation-on-the-rate-of-pathologic-complete-response-in-vitamin-d-deficient-patients-100414530","NCT04677816","Impact of Vitamin D Supplementation on the Rate of Pathologic Complete Response in Vitamin D Deficient Patients","Impact of Vitamin D Supplementation on the Rate of Pathologic Complete Response in Vitamin D Deficient Patients Receiving Neoadjuvant Chemotherapy for Operable Triple Negative Breast Cancer","Inclusion Criteria:\n\n* Women or men with histologically confirmed invasive mammary carcinoma.\n* Known triple negative ER\u002FPR\u002FHER2 receptor status as defined by:\n\n  * ER and PR less than or equal to 10% and\n  * HER2 negative based on one of the following:\n  * IHC 0 or 1+\n  * IHC 2+ and FISH negative\n  * IHC 2+ and FISH equivocal and no indication for HER2 targeted therapy based on the treating investigators discretion (i.e., HER2: CEP17 ratio \\\u003C 2.0 or HER2 total copy number \\\u003C6)\n* Patients who plan to undergo neoadjuvant chemotherapy prior to definitive surgical management. Participants are eligible up to 2 weeks after initiating neoadjuvant chemotherapy.\n* ECOG performance status of 0, 1 or 2.\n* Age ≥ 18.\n* The effects of high dose vitamin D on the developing human fetus are unknown. For this reason, women of child-bearing potential must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately.\n* Ability to understand and the willingness to sign an IRB-approved informed consent document (either directly or via a legally authorized representative).\n\nExclusion Criteria:\n\n* Patients with nephrolithiasis within the past year.\n* Patients with known sarcoidosis.\n* Patients with corrected calcium \\>10.5 mg\u002FdL within 30 days prior to initiation of chemotherapy.\n* History of allergic reactions attributed to compounds of similar chemical or biologic composition to vitamin D.\n* Pregnant women are excluded from this study because vitamin D supplementation greater than the recommended daily allowance (RDA) is a pregnancy class C agent with no adequate or well controlled studies in humans.\n* Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with high dose vitamin D (greater than RDA), women who are breastfeeding are excluded from this study.\n* Prior treatment for this malignancy including surgery, radiation therapy, chemotherapy, hormonal therapy or investigational agent prior to study entry.\n* Patients currently taking Vitamin D at a dose of 50,000 International Units (IU) once weekly.",{"count":161,"type":21},50,[163],"PHASE2","A two arm pilot study investigating the rate of pathologic complete response in patients with vitamin D deficiency and triple negative breast cancer undergoing standard neoadjuvant chemotherapy + vitamin D supplementation, including an observational arm to describe response in patients who are not deficient. Investigators hypothesize that vitamin D supplementation during neoadjuvant chemotherapy in operable triple negative breast cancer patients with vitamin D deficiency, will increase the rate of pathologic complete response chain reaction to that of vitamin D sufficient patients based on historical controls.",[166,29,167],"Triple Negative Breast Cancer","Invasive Breast Cancer","2026-04-09",{"date":170,"type":41},"2026-04-14",{"date":172,"type":41},"2021-10-22",{"date":174,"type":21},"2026-08",{"name":176,"class":48},"Wake Forest University Health Sciences",{"id":178,"slug":179,"hasResults":11,"nctId":180,"briefTitle":181,"officialTitle":182,"acronym":4,"eligibilityCriteria":183,"healthyVolunteers":57,"sex":17,"minAge":4,"maxAge":18,"enrollmentInfo":184,"targetDuration":4,"studyType":22,"phases":186,"briefSummary":187,"conditions":188,"keywords":4,"overallStatus":143,"whyStopped":4,"lastUpdateSubmitDate":190,"lastUpdatePostDateStruct":191,"startDateStruct":193,"completionDateStruct":195,"leadSponsor":197,"locationsCount":49},"100632413","the-role-of-urinary-rhoa-ngf-and-bdnf-levels-in-overactive-bladder-and-vitamin-d-deficiency-100632413","NCT07513363","The Role of Urinary RhoA, NGF, and BDNF Levels in Overactive Bladder and Vitamin D Deficiency","The Role of Urinary RhoA, NGF, and BDNF Levels in Diagnosis and Follow-up in Children With Overactive Bladder and Vitamin D Deficiency.","Inclusion Criteria:\n\n* Children aged 4-18 years presenting with active OAB symptoms (frequency, urgency)\n\nExclusion Criteria:\n\n* Neurological diseases\n* Malignancy\n* Active urinary tract infections\n* Anatomical bladder anomalies\n* History of prior OAB treatment\u002Furological surgery.",{"count":185,"type":21},52,[62],"The primary aim of this study is to evaluate the role of three specific urinary proteins-RhoA, Nerve Growth Factor (NGF), and Brain-Derived Neurotrophic Factor (BDNF)-as potential biomarkers for the diagnosis and follow-up of children aged 4-18 diagnosed with Overactive Bladder (OAB) and Vitamin D deficiency.",[189,29],"Overactive Bladder","2026-04-01",{"date":192,"type":41},"2026-04-07",{"date":194,"type":21},"2026-05-01",{"date":196,"type":21},"2027-01-01",{"name":198,"class":48},"Tarik Emre Sener",{"id":200,"slug":201,"hasResults":11,"nctId":202,"briefTitle":203,"officialTitle":203,"acronym":4,"eligibilityCriteria":204,"healthyVolunteers":11,"sex":205,"minAge":206,"maxAge":207,"enrollmentInfo":208,"targetDuration":4,"studyType":22,"phases":210,"briefSummary":211,"conditions":212,"keywords":214,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":216,"lastUpdatePostDateStruct":217,"startDateStruct":219,"completionDateStruct":221,"leadSponsor":223,"locationsCount":49},"100389798","evaluation-of-the-clinical-and-psychological-impact-of-vitamin-d-replacement-in-adolescent-females-at-risk-for-polycystic-ovarian-syndrome-pcos-100389798","NCT04355572","Evaluation of the Clinical and Psychological Impact of Vitamin D Replacement in Adolescent Females at Risk for Polycystic Ovarian Syndrome (PCOS)","Inclusion Criteria:\n\n\\- Postmenarchal adolescent females aged 13-21 who meet modified Rotterdam criteria for PCOS, with a serum vitamin D level between 6-29 ng\u002FmL.\n\nExclusion Criteria:\n\n* Other causes for hyperandrogenism,\n* Chronic renal diseases,\n* Acquired or inherited calcium and vitamin D metabolic disorders.","FEMALE","13 Years","21 Years",{"count":209,"type":21},60,[62],"This study is a double blind, placebo controlled, randomized trial of study subjects with PCOS and low vitamin D to 2 groups- placebo and vitamin D replacement. Participants and investigators will be blinded to treatment modality until the end of the trial period",[213,29],"Polycystic Ovarian Syndrome in Adolescent Females",[215],"Anti-Mullerian Hormone (AMH)","2026-02-19",{"date":218,"type":41},"2026-02-23",{"date":220,"type":21},"2026-05",{"date":222,"type":21},"2027-12-01",{"name":224,"class":48},"Yale University",{"id":226,"slug":227,"hasResults":11,"nctId":228,"briefTitle":229,"officialTitle":229,"acronym":4,"eligibilityCriteria":230,"healthyVolunteers":11,"sex":231,"minAge":232,"maxAge":233,"enrollmentInfo":234,"targetDuration":4,"studyType":22,"phases":236,"briefSummary":237,"conditions":238,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":241,"lastUpdatePostDateStruct":242,"startDateStruct":244,"completionDateStruct":246,"leadSponsor":247,"locationsCount":49},"100621157","is-there-a-benefit-from-addition-of-exercise-in-diabetic-patients-with-ed-who-complain-low-vitamin-d-100621157","NCT07366970","Is There a Benefit From Addition of Exercise in Diabetic Patients With ED Who Complain Low Vitamin D?","Inclusion Criteria:\n\n* diabetic men (forty)\n* type 2 diabetes\n* complaint of erectile dysfucntion (chronic complaint more than 24 months)\n* men with low vitamin D (deiciency in vitamin D)\n\nExclusion Criteria:\n\n* cardiac patients\n* respiratory disease patients\n* renal disease\n* liver disease","MALE","35 Years","45 Years",{"count":235,"type":21},40,[62],"males with diabetes complain impotence in the presence of low vitamin D deficiency. pharacmological treatment of low vitamin D levels is necessary but changing lifestyle by performing exercise is also important",[239,240,29],"Diabetes Mellitus","Erectile Dysfunction","2026-01-17",{"date":243,"type":41},"2026-01-26",{"date":245,"type":41},"2025-12-05",{"date":144,"type":21},{"name":248,"class":48},"Cairo University",{"id":250,"slug":251,"hasResults":11,"nctId":252,"briefTitle":253,"officialTitle":253,"acronym":4,"eligibilityCriteria":254,"healthyVolunteers":11,"sex":205,"minAge":18,"maxAge":90,"enrollmentInfo":255,"targetDuration":257,"studyType":92,"phases":4,"briefSummary":258,"conditions":259,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":262,"lastUpdatePostDateStruct":263,"startDateStruct":265,"completionDateStruct":267,"leadSponsor":269,"locationsCount":49},"100597351","effect-of-vitamin-d-deficiency-on-the-frequency-and-severity-of-spinal-anesthesia-induced-hypotension-in-pregnant-women-undergoing-cesarean-section-100597351","NCT07057362","Effect of Vitamin D Deficiency on the Frequency and Severity of Spinal Anesthesia-Induced Hypotension in Pregnant Women Undergoing Cesarean Section","Inclusion Criteria:\n\n* Pregnant women aged 18 years or older\n* Scheduled for elective cesarean delivery under spinal anesthesia\n* Able and willing to provide written informed consent\n\nExclusion Criteria:\n\n* Emergency cesarean sections\n* History of significant cardiovascular disease (e.g., arrhythmia, heart failure)\n* Known neurological disorders affecting autonomic function\n* Current vitamin D supplementation within the past 30 days\n* Inability to undergo blood sampling or provide valid hemodynamic data\n* Contraindication to spinal anesthesia",{"count":256,"type":21},140,"1 Day","Spinal anesthesia-induced hypotension remains a common and significant complication during cesarean sections, posing risks for both mother and fetus. Vitamin D deficiency, frequently observed in pregnant women, is associated with altered vascular function and potential hemodynamic instability. This prospective observational study aims to investigate whether vitamin D deficiency is associated with an increased incidence and severity of spinal anesthesia-induced hypotension in pregnant women undergoing elective cesarean delivery. Vitamin D levels will be measured preoperatively, and intraoperative hemodynamic parameters will be closely monitored. The findings could contribute to improved management strategies for pregnant patients at risk of severe hypotension.",[260,29,261],"Spinal Anesthesia-induced Hypotension","Cesarean Section","2026-01-02",{"date":264,"type":41},"2026-01-06",{"date":266,"type":41},"2025-03-01",{"date":268,"type":21},"2025-12-30",{"name":270,"class":48},"Duzce University",{"id":272,"slug":273,"hasResults":11,"nctId":274,"briefTitle":275,"officialTitle":276,"acronym":277,"eligibilityCriteria":278,"healthyVolunteers":57,"sex":17,"minAge":18,"maxAge":279,"enrollmentInfo":280,"targetDuration":4,"studyType":22,"phases":282,"briefSummary":283,"conditions":284,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":285,"lastUpdatePostDateStruct":286,"startDateStruct":288,"completionDateStruct":290,"leadSponsor":292,"locationsCount":49},"100617377","effects-of-different-vitamin-d3-formulations-in-vitamin-d-deficient-adults-100617377","NCT07317830","Effects of Different Vitamin D3 Formulations in Vitamin D-Deficient Adults","The Effects of Eight Weeks of Supplementation With Two Vitamin D₃ Formulations in Adults With Subclinical and Clinical Vitamin D Deficiency: A Randomized Controlled Superiority Pilot Trial","AMORPH-D","Inclusion Criteria:\n\n* Adults aged 18 years and over\n* Serum 25(OH)D \\\u003C 75 nmol\u002FL\n* BMI 18.5 - 29.9 kg\u002Fm2\n* Free of clinically significant acute disorders and severe chronic diseases\n* No planned travel to high-UV destinations or tanning bed use during the trial\n* Willing to avoid non-study vitamin D supplements\n* Able to give written informed consent and comply with study visits\n* Submitted informed consent\n\nExclusion Criteria:\n\n* Pregnancy of breast feeding\n* Underweight or obesity\n* History of any dietary supplement use within 8 weeks before screening\n* Medications that materially alter vitamin D metabolism or calcium balance\n* Subjects with a history of medicine or alcohol abuse\n* Abnormal values for lab clinical chemistry (\\> 2 SD)\n* Unwillingness to return for follow-up analysis\n* Participation in other clinical trials within 60 days prior to screening","80 Years",{"count":281,"type":21},20,[62],"This randomized controlled superiority pilot trial will evaluate the efficacy of two vitamin D3 formulations administered over eight weeks in adults with subclinical or clinical vitamin D deficiency. The study will compare changes in serum 25-hydroxyvitamin D concentrations between formulations, as well as the proportion of participants who will achieve vitamin D sufficiency. Both formulations are expected to improve vitamin D status, with the hypothesis that one formulation will demonstrate superior bioavailability, resulting in greater and faster increases in circulating 25-hydroxyvitamin D. The findings will provide preliminary evidence to inform formulation selection and dosing strategies for correcting vitamin D deficiency and will support the design of larger, confirmatory trials.",[29],"2025-12-24",{"date":287,"type":41},"2026-01-05",{"date":289,"type":21},"2025-12-15",{"date":291,"type":21},"2026-06-15",{"name":293,"class":48},"Center for Health Sciences, Serbia",{"id":295,"slug":296,"hasResults":11,"nctId":297,"briefTitle":298,"officialTitle":299,"acronym":300,"eligibilityCriteria":301,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":302,"enrollmentInfo":303,"targetDuration":4,"studyType":22,"phases":305,"briefSummary":307,"conditions":308,"keywords":311,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":315,"lastUpdatePostDateStruct":316,"startDateStruct":318,"completionDateStruct":320,"leadSponsor":322,"locationsCount":324},"100300264","phase-3-the-vitdalize-study-effect-of-high-dose-vitamin-d3-on-28-day-mortality-in-adult-critically-ill-patients-100300264","NCT03188796","The VITDALIZE Study: Effect of High-dose Vitamin D3 on 28-day Mortality in Adult Critically Ill Patients","The VITDALIZE Study: Effect of High-dose Vitamin D3 on 28-day Mortality in Adult Critically Ill Patients With Severe Vitamin D Deficiency: a Multicenter, Placebo-controlled Double-blind Phase III Randomized Controlled Trial (RCT)","VITDALIZE","Inclusion Criteria:\n\n* ≥18 years\n* Anticipated ICU stay ≥ 48 hours\n* Admission to ICU ≤ 72 hours before screening\n* Severe vitamin D deficiency (≤12 ng\u002Fml or undetectable)\n\nExclusion Criteria:\n\n* Severe gastrointestinal dysfunction (\\> 400 ml residual volume)\u002Funable to take study medication\n* Do not resuscitate (DNR) order\u002Fimminent death\n* hypercalcemia\n* known recent nephrolithiasis, active tuberculosis or sarcoidosis\n* pregnancy\u002Flactation\n* not deemed appropriate by study team\u002Fphysician","100 Years",{"count":304,"type":21},2400,[306],"PHASE3","In the VITdAL-ICU trial using a large oral dose of vitamin D3 in 480 adult critically ill patients, there was no benefit regarding the primary endpoint hospital length of stay. However, the predefined subgroup with severe vitamin D deficiency (25(OH)D ≤ 12ng\u002Fml) had significantly lower 28-day mortality (36.3% placebo vs. 20.4% vitamin D group, hazard ratio (HR) 0.52 (0.30-0.89), number needed to treat = 6). Therefore, high-dose vitamin D3 in a population of severely vitamin D deficient critically ill patients is a promising and inexpensive intervention that requires confirmatory multicenter studies.\n\nTo date, only 7 interventions (e.g. noninvasive ventilation or prone positioning) have ever demonstrated mortality benefit for Intensive Care Unit (ICU) patients in multicenter trials. In case of benefit, vitamin D treatment in critically ill patients could be immediately implemented worldwide.",[309,29,310],"Critical Illness","Covid19",[312,313,314],"vitamin D","critical care","COVID-19","2025-11-18",{"date":317,"type":41},"2025-11-21",{"date":319,"type":41},"2017-10-10",{"date":321,"type":21},"2027-03",{"name":323,"class":48},"Medical University of Graz",18,{"id":326,"slug":327,"hasResults":11,"nctId":328,"briefTitle":329,"officialTitle":330,"acronym":4,"eligibilityCriteria":331,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":332,"targetDuration":4,"studyType":22,"phases":334,"briefSummary":335,"conditions":336,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":339,"lastUpdatePostDateStruct":340,"startDateStruct":342,"completionDateStruct":344,"leadSponsor":346,"locationsCount":348},"100550734","phase-2-vitamin-a-supplementation-in-allogeneic-stem-cell-transplantation-100550734","NCT06450925","Vitamin A Supplementation in Allogeneic Stem Cell Transplantation.","A Randomized Double Blinded Trial of Vitamin A Supplementation in Allogeneic Stem Cell Transplantation.","Inclusion Criteria:\n\n* Be 18 years of age or older\n* Be scheduled for allogeneic stem cell transplant.\n* Have a vitamin A level \\\u003C upper limit of normal for age.\n* Be able to tolerate enteral vitamin dose administration.\n* Have a total bilirubin level \\\u003C 1.5x ULN and an AST and\u002For ALT\\\u003C 3xULN for age\n* Receiving PBSCs as stem cell graft\n\nExclusion Criteria:\n\n* Ongoing raised intracranial pressure\n* Liver cirrhosis\n* Patients will be excluded if they are currently pregnant.",{"count":333,"type":21},190,[163],"The investigators hypothesize that single oral high dose supplementation with vitamin A will reduce the incidence of moderate-severe chronic graft-versus-host disease (GVHD) compared with placebo.",[337,338,29],"Graft Vs Host Disease","Vitamin A Deficiency","2025-08-11",{"date":341,"type":41},"2025-08-12",{"date":343,"type":41},"2025-03-25",{"date":345,"type":21},"2029-08",{"name":347,"class":48},"Children's Hospital Medical Center, Cincinnati",3,{"id":350,"slug":351,"hasResults":11,"nctId":352,"briefTitle":353,"officialTitle":354,"acronym":4,"eligibilityCriteria":355,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":356,"targetDuration":4,"studyType":22,"phases":358,"briefSummary":359,"conditions":360,"keywords":368,"overallStatus":143,"whyStopped":4,"lastUpdateSubmitDate":373,"lastUpdatePostDateStruct":374,"startDateStruct":376,"completionDateStruct":378,"leadSponsor":380,"locationsCount":4},"100505635","clinical-trial-of-vit-d-and-calcium-for-recurrent-bppv-100505635","NCT05863949","Clinical Trial of Vit D and Calcium for Recurrent BPPV","STOP Vertigo: Supplementation of Vitamin D for Termination of Recurrences From Benign Paroxysmal Positional Vertigo","Inclusion Criteria:\n\n* Age 18 years or older\n* 2 or more distinct episodes of benign paroxysmal positional vertigo within a 12-month period on history\n* At least 1 episode diagnosed based on physical examination by trained study personnel, meeting the diagnostic criteria of the Bárány Society\n* Episodes separated in time, with a minimum of 1 week symptom-free between episodes\n* Serum evidence of Vitamin D deficiency, as evidenced by 25-hydroxy vitamin D level of \\\u003C75 nmol\u002FL (\\\u003C30 ng\u002FmL)48\n* Subject able to provide informed consent to participate in the study\n\nExclusion Criteria:\n\nPotential subjects will be excluded if they\n\n* have another identifiable cause of vertigo identified on history or physical examination\n* have a history of allergy or medically significant adverse reaction to vitamin D or calcium carbonate\n* have a chronic medical disorder which is a contraindication to vitamin D or calcium carbonate supplementation, including uncontrolled hyperparathyroidism, nephrolithiasis, or GI malabsorption disorders\n* are on loop diuretic agents or thiazides\n* have a contraindication to routine bloodwork for study purposes, including being hospitalized with a critical illness, cellulitis at blood draw sites, or presence of vascular grafts.",{"count":357,"type":21},860,[62],"Randomized double blind placebo controlled trial of vitamin D supplements, with or without calcium supplementation, versus placebo in reduction of recurrences in BPPV.",[361,362,363,364,365,366,29,367],"BPPV","Benign Paroxysmal Positional Vertigo","Vertigo","Vertigo, Peripheral","Dizziness","Dizziness; Epidemic","Calcium Deficiency",[369,370,371,372,312],"bppv","benign paroxysmal positional vertigo","vertigo","dizziness","2025-06-20",{"date":375,"type":41},"2025-06-25",{"date":377,"type":21},"2025-08",{"date":379,"type":21},"2026-09",{"name":381,"class":48},"Ottawa Hospital Research Institute",{"id":383,"slug":384,"hasResults":11,"nctId":385,"briefTitle":386,"officialTitle":387,"acronym":4,"eligibilityCriteria":388,"healthyVolunteers":11,"sex":17,"minAge":389,"maxAge":390,"enrollmentInfo":391,"targetDuration":4,"studyType":92,"phases":4,"briefSummary":392,"conditions":393,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":397,"lastUpdatePostDateStruct":398,"startDateStruct":400,"completionDateStruct":402,"leadSponsor":404,"locationsCount":49},"100387968","high-dose-interval-vitamin-d-supplementation-in-patients-with-inflammatory-bowel-disease-receiving-biologic-therapy-100387968","NCT04331639","High Dose Interval Vitamin D Supplementation in Patients With Inflammatory Bowel Disease Receiving Biologic Therapy","Implementation of High Dose Interval Vitamin D Supplementation in Patients With Inflammatory Bowel Disease Receiving Infliximab or Vedolizumab","Inclusion Criteria:\n\n* Existing diagnosis of IBD, including Crohn disease, ulcerative colitis, and indeterminate colitis\n* Receiving treatment with Infliximab or Vedolizumab every 4-8 weeks\n* Age 5-25 years old, at study entry\n* Measured serum level of 25-OHD of less than 40 ng\u002FmL in the last 4-8 weeks and no changes in vitamin D supplementation in the interim. Of note, 25-OHD levels are evaluated routinely as part of standard clinical care for IBD\n\nExclusion Criteria:\n\n* History of any underlying kidney disease\n* History of preexisting liver disease\n* History of granulomatous disease\n* Inability to take oral vitamin D3 as a pill\n* History of hypercalcemia or hypercalciuria\n* Currently, or within the past 3 months, taking an anti-epileptic medication or Lasix","5 Years","25 Years",{"count":161,"type":21},"The investigators will be administering oral high dose interval vitamin D, concurrently when participants are receiving biologic therapy for their inflammatory bowel disease. The investigators will be collecting some additional bloodwork and questionnaires at the time of participants infusions.",[394,395,396,29],"Inflammatory Bowel Disease","Crohn Disease","Ulcerative Colitis","2025-02-27",{"date":399,"type":41},"2025-03-03",{"date":401,"type":41},"2020-11-01",{"date":403,"type":21},"2025-12-31",{"name":405,"class":48},"Boston Children's Hospital",{"id":407,"slug":408,"hasResults":11,"nctId":409,"briefTitle":410,"officialTitle":411,"acronym":4,"eligibilityCriteria":412,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":413,"targetDuration":415,"studyType":92,"phases":4,"briefSummary":416,"conditions":417,"keywords":420,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":428,"lastUpdatePostDateStruct":429,"startDateStruct":431,"completionDateStruct":433,"leadSponsor":435,"locationsCount":49},"100579891","investigating-the-relationship-between-temporal-bone-ct-bone-density-and-hearing-loss-in-otosclerosis-patients-100579891","NCT06830187","Investigating the Relationship Between Temporal Bone CT, Bone Density, and Hearing Loss in Otosclerosis Patients","Radiological and Audiological Correlation in Otosclerosis: a Prospective Case-Control Study Evaluating Temporal Bone CT, Bone Mineral Density, and Hearing Loss","Inclusion Criteria (Otosclerosis Group):\n\n* Adults diagnosed with otosclerosis based on audiological and clinical assessment\n* Patients with available high-resolution CT scans and audiological data\n* Individuals who have undergone stapedectomy or stapedotomy surgery\n* Availability of bone mineral density and serum vitamin D data\n\nInclusion Criteria (Control Group):\n\n* Patients without otosclerosis but with temporal CT imaging for other indications\n* No history of conductive or mixed hearing loss\n* Availability of BMD and vitamin D data\n\nExclusion Criteria:\n\n* History of primary metabolic bone diseases (osteoporosis, Paget's disease)\n* Use of medications affecting bone metabolism (bisphosphonates, corticosteroids)\n* History of chronic otitis media or prior ear surgeries\n* Patients who received head and neck radiotherapy",{"count":414,"type":21},86,"2 Months","The goal of this observational case-control study is to evaluate the relationship between temporal bone computed tomography (CT) findings, bone mineral density (BMD), and audiological parameters in adults diagnosed with otosclerosis. The main questions it aims to answer are:\n\nIs there a correlation between temporal bone CT density values and the severity of hearing loss in otosclerosis? Do bone mineral density and serum vitamin D levels differ between otosclerosis patients and individuals without otosclerosis? Researchers will compare patients diagnosed with otosclerosis to a control group without otosclerosis to determine if CT-based density variations are associated with disease severity and systemic bone metabolism markers.\n\nParticipants who have already had a temporal bone CT scan as part of their routine clinical evaluation will undergo:\n\nBone mineral density (BMD) assessment via dual-energy X-ray absorptiometry (DEXA) Serum vitamin D level measurement Audiological testing, including pure tone audiometry and speech discrimination tests This study aims to improve the diagnostic and prognostic understanding of otosclerosis by integrating imaging, metabolic, and audiological data.",[418,419,29],"Otosclerosis of Middle Ear","Bone Density",[421,422,423,424,425,426,427],"Otosclerosis","Temporal Bone CT","Bone Mineral Density (BMD)","Serum Vitamin D","Audiology","Stapedectomy","Hounsfield Units","2025-02-19",{"date":430,"type":41},"2025-02-20",{"date":432,"type":41},"2022-01-01",{"date":434,"type":21},"2025-05-01",{"name":436,"class":48},"İbrahim Emir Yeşil",{"id":438,"slug":439,"hasResults":11,"nctId":440,"briefTitle":441,"officialTitle":442,"acronym":4,"eligibilityCriteria":443,"healthyVolunteers":57,"sex":17,"minAge":18,"maxAge":444,"enrollmentInfo":445,"targetDuration":4,"studyType":22,"phases":447,"briefSummary":448,"conditions":449,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":452,"lastUpdatePostDateStruct":453,"startDateStruct":454,"completionDateStruct":456,"leadSponsor":458,"locationsCount":460},"100361717","phase-2-vitamin-d-and-polycystic-ovarian-syndrome-pcos-100361717","NCT03989778","Vitamin D and Polycystic Ovarian Syndrome (PCOS)","Efficacy of Vitamin D Supplementation and Metformin Compared to Metformin Alone for Improvement in Follicle Size of Infertile Females With Polycystic Ovary Syndrome: a Randomized Open Label Trial","Inclusion Criteria:\n\n* Females with age range 18- 36 years, from all ethnic background having primary infertility with diagnosis of PCOS when at least 2 of these 3 elements are present: hyperandrogenism, chronic anovulation and polycystic ovaries and Vitamin D deficiency serum levels \\\u003C 25 nmol\u002FL\n\nExclusion Criteria:\n\nexclusion criteria at baseline will be excluded from the study\n\n* Females with secondary Infertility\n* Hypercalcemia (plasma calcium concentrations\\> 2.65 mmol\u002FL)\n* Exclude women with Tuberculosis or other granulomatous disorders.\n* Women receiving vitamin D replacement, oral contraceptives, hormonal replacement therapy, glucocorticoids, calcium supplementation, insulin-sensitizing drugs(incretin mimetic drugs, thiazolidinedione, sulfonylurea), lipid-lowering drugs or other drugs affecting insulin sensitivity or serum androgens (e.g., niacin, corticosteroids, beta-blockers, calcium channel blockers, thiazide diuretics), anti-epileptics, anti-retroviral, cholestyramine, anti-fungal, statins, H2 blockers, immunosuppressants, chemotherapeutic agents, antimicrobials (Rifampicin, isoniazid, hydroqychloroquin) or any other drug modifying lipid metabolism in the previous 3 months prior to study\n* Women with congenital adrenal hyperplasia, Cushing's syndrome, androgen-secreting tumors, type 2 diabetes mellitus, renal, hepatic or thyroid disorders, hyperparathyroidism, malabsorption syndromes, Chronic Kidney Disease Hepatic failure, cystic fibrosis, vaginal bleeding of unknown etiology Women Those who had Bariatric surgery will also be excluded.","36 Years",{"count":446,"type":21},300,[163],"Primary Objectives:\n\nTo evaluate the efficacy of metformin and Vitamin D supplementation on serum insulin and serum androgen levels (Total testosterone, Steroid Hormone Binding Globulin, Free Androgen Index) levels compared metformin alone in infertile Poly cystic ovarian females of reproductive age group.\n\nSecondary Objectives:\n\nTo measure change in endometrial thickness\u002Fnumber of follicles and follicular size by day 12 trans-vaginal ultrasound in the intervention group i.e. combination of metformin and vitamin D supplementation",[450,451,29],"Infertility, Female","Infertility","2025-02-17",{"date":428,"type":41},{"date":455,"type":41},"2023-02-01",{"date":457,"type":21},"2025-07-13",{"name":459,"class":48},"Aga Khan University",2,{"id":462,"slug":463,"hasResults":11,"nctId":464,"briefTitle":465,"officialTitle":466,"acronym":4,"eligibilityCriteria":467,"healthyVolunteers":57,"sex":205,"minAge":18,"maxAge":4,"enrollmentInfo":468,"targetDuration":4,"studyType":92,"phases":4,"briefSummary":470,"conditions":471,"keywords":472,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":475,"lastUpdatePostDateStruct":476,"startDateStruct":478,"completionDateStruct":480,"leadSponsor":482,"locationsCount":49},"100376273","vitamin-d-and-health-status-of-british-african-caribbean-women-100376273","NCT04179370","Vitamin D and Health Status of British African-Caribbean Women","The Relationship Between Sun Exposure, Diet, Lifestyle and Bone on Vitamin D Status (25OHD) in British African-Caribbean Women Living in Southern United Kingdom","Inclusion Criteria:\n\n* Women\n* British African-Caribbean Self-reported Having African ancestral origin and migrated via the Caribbean islands, or having at least one parent with African ancestral origin that migrated via the Caribbean\n* Living in England for \\>2 months\n* Aged 18-35 or \\>55 years\n* No significant health issues\n* Pre-menopausal (regular menstrual periods) or Post-menopausal (menstrual periods stopped for longer than 12 consecutive months)\n* BMI 18-30kg\u002Fm2\n\nExclusion Criteria:\n\n* Women in perimenopause or menopause\n* Pregnant or planning pregnancy during study period\n* Hypercalcaemia (\\>2.5mmol\u002FL) - assessed and excluded at baseline\n* Currently receiving treatment for medical conditions that are likely to affect vitamin D metabolism (osteoporosis, hormone replacement therapy, anti-estrogens treatment, antiepileptic drugs and breast cancer treatment)\n* Regular use of sun beds\n* Having a sun holiday one month prior to commencing study or plans for a sun holiday for more than 4 weeks within the study period\n* Women who take vitamin D or calcium supplements (or multivitamin supplements that contain these vitamins) - If potential participant agrees to stop supplement use to join the study, a wash-out period of 8 weeks prior to commencing the study is acceptable\n* Living in England for less than 2 months",{"count":469,"type":21},100,"Vitamin D deficiency remains a global public health issue (Wilson 2017). In the United Kingdom (UK). There is a lack of research looking at vitamin D status of the British African-Caribbean population. This population is particularly at risk to vitamin D deficiency due to possessing a skin type which hinders the production of vitamin D in the skin. Further, due to the geographical location of the UK, there is reduced ability to produce vitamin D due to the low sun exposure (Libon 2013 ). Our main source of vitamin D is through skin exposure to the sun. In the UK, the UV radiation is only strong enough in April-September (Wilson 2017) for the production of vitamin D to occur. In winter months, vitamin D needs to be consumed in food or supplement form. Vitamin D is essential for healthy bones and is associated with reduced risk of certain cancers and immune disorders (Wilson 2017). There is strong epidemiological evidence linking low vitamin D status with diabetes, cardiovascular disease, osteoporosis, osteoarthritis and some cancers (NatCen 2018).\n\nThis observational study will aim to determine the vitamin D status of British Afro-Caribbean women, as well as determine the effects of sun exposure, dietary vitamin D intake, muscular strength, lifestyle and anthropometrical (height, weight etc.) factors have on vitamin D status. The study will be conducted at the University of Surrey. The study will take place in Autumn and winter 2019\u002F2020 and a repeat study in Spring 2020. Each participant will require two visits to the university, each session will take approximately 2 hours. The study is funded by the University of Surrey. The findings of this study may lead to strategies for improving vitamin D status in this population, as well as improving guidelines to assist darker-skinned people regarding sunlight exposure in high latitudes.",[29],[473,474],"vitamin D OR 25(OH)D","African-Caribbean OR Afro-Caribbean","2024-12-11",{"date":477,"type":41},"2024-12-16",{"date":479,"type":41},"2020-02-07",{"date":481,"type":21},"2025-03-31",{"name":483,"class":48},"University of Surrey",{"id":485,"slug":486,"hasResults":11,"nctId":487,"briefTitle":488,"officialTitle":489,"acronym":4,"eligibilityCriteria":490,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":491,"targetDuration":4,"studyType":22,"phases":493,"briefSummary":494,"conditions":495,"keywords":496,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":499,"lastUpdatePostDateStruct":500,"startDateStruct":502,"completionDateStruct":504,"leadSponsor":506,"locationsCount":49},"100511311","early-vitamin-d3-supplementation-for-critically-ill-patients-100511311","NCT05937789","Early Vitamin D3 Supplementation for Critically Ill Patients","Effects of Early Vitamin D3 Supplementation on Clinical Outcomes for Critically Ill Patients","Inclusion Criteria:\n\n* ≥18-year-old critically ill patient.\n* ICU admission \\\u003C 24 hours.\n* Baseline 25(OH)D levels within 24 hours of ICU admission \\\u003C 20 ng\u002FmL.\n* Expected ICU length of stay ≥ 72 hours.\n\nExclusion Criteria:\n\n* Hypercalcemia (ie. total serum calcium levels \\> 2.6 mmol\u002FL).\n* Disorders affecting serum 25(OH)D levels, calcium metabolism, or bone metabolism (eg, parathyroid disease, rickets, or severe cirrhosis \\[Child C\\]).\n* Having received high-dose vitamin D3 therapy (ie. \\> 2,000 IU daily or a single dose of ≥ 10,000 IU) within the past four weeks.\n* Active COVID-19 at ICU admission.\n* Organ transplant.\n* Having had tuberculosis, sarcoidosis or kidney stones within the past year.\n* Having renal dialysis, continuous kidney replacement therapy (CKRT), acute kidney injury (AKI).\n* Having ICU admission within the past three months.\n* Non-native-speaking patients and their families\n* Pregnant women.",{"count":492,"type":21},240,[62],"There are no clear international guidelines for dosing vitamin D based on deficiency severity. Therefore, a new clinical trial is needed to evaluate the benefits of early vitamin D supplementation in maintaining sufficient levels for critically ill patients. The investigators conducted a multicenter clinical trial in Taiwan focusing on vitamin D and critically ill patients. 240 patients with low calcidiol levels will be enrolled and be provided varying supplementation doses to maintain their serum calcidiol levels ≥ 30 ng\u002FmL within 30 days of ICU admission. The serum levels of calcidiol and PTH will be measured on Day 0, Day 7, Day 14 and Day 30 before and after vitamin D supplementation. The results will serve as a valuable reference for intensivists when formulating appropriate vitamin D treatment strategy to maximize clinical benefits for critically ill patients.",[29,309],[312,497,498],"calcidiol levels","critically ill","2024-08-14",{"date":501,"type":41},"2024-08-16",{"date":503,"type":41},"2024-01-22",{"date":505,"type":21},"2026-12-31",{"name":507,"class":48},"National Taiwan University Hospital",{"id":509,"slug":510,"hasResults":11,"nctId":511,"briefTitle":512,"officialTitle":513,"acronym":4,"eligibilityCriteria":514,"healthyVolunteers":11,"sex":17,"minAge":89,"maxAge":4,"enrollmentInfo":515,"targetDuration":4,"studyType":22,"phases":516,"briefSummary":517,"conditions":518,"keywords":520,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":499,"lastUpdatePostDateStruct":521,"startDateStruct":522,"completionDateStruct":524,"leadSponsor":526,"locationsCount":49},"100473794","vitamin-d-for-critically-traumatic-patients-100473794","NCT05449522","Vitamin D for Critically Traumatic Patients","Effects of High Doses of Liquid Vitamin D Supplementation on Clinical Outcomes in Critically Traumatic Patients.","Inclusion Criteria:\n\n* Major trauma adult (\\> 20 years old) with Injury Severity Score equal or higher than 9, who is admitted to ICU\n\nExclusion Criteria:\n\nPatients with the following conditions:\n\n* Chronic liver disease\n* Contraindication to enteral feeds\n* Hypercalcemia\n* Current use of vitamin D, estrogen, or medications for bone disease\n* High risk of hypercalcemia, ex. metastatic cancer, primary hyperparathyroidism, sarcoidosis, multiple myeloma",{"count":469,"type":21},[62],"Trauma has been an important global public health issue. Yet it is the sixth cause of death in Taiwan, trauma brings great negative impact to national productivity since it presents specifically as the leading cause of death for the population aged below 40 years. According to the national databank from Formosa Association for the Surgery of Trauma, mortality rate in critically traumatic patients with injury severity score (ISS) ≥ 25 is as high as 23%. Vitamin D, a pleiotropic hormone, regulates directly functions of most organs and immune system. It has been proven that vitamin D insufficiency or deficiency would deteriorate survival of critically ill patients, while supplementation of high-dose vitamin D ameliorates the clinical outcomes. This study investigates whether multiple high doses of vitamin D supplementation in one week can decrease the mortality and morbidity in critically traumatic patients. The serum levels of calcidiol and PTH will be measured on Day 0, Day 3, Day 10, Day 15, Day 30 and Day 60 before and after vitamin D supplementation.",[29,519],"Major Trauma",[70,519],{"date":501,"type":41},{"date":523,"type":41},"2018-05-01",{"date":525,"type":21},"2026-07-01",{"name":507,"class":48},{"id":528,"slug":529,"hasResults":11,"nctId":530,"briefTitle":531,"officialTitle":532,"acronym":533,"eligibilityCriteria":534,"healthyVolunteers":11,"sex":17,"minAge":535,"maxAge":4,"enrollmentInfo":536,"targetDuration":4,"studyType":22,"phases":538,"briefSummary":539,"conditions":540,"keywords":542,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":546,"lastUpdatePostDateStruct":547,"startDateStruct":549,"completionDateStruct":551,"leadSponsor":553,"locationsCount":49},"100505354","phase-4-oral-vitamin-d-supplementation-prevent-peritoneal-dialysis-related-peritonitis-100505354","NCT05860270","Oral Vitamin D Supplementation Prevent Peritoneal Dialysis-related Peritonitis","The Effects of Oral Vitamin D Supplementation on the Prevention of Peritoneal Dialysis-related Peritonitis, a Multicenter Randomized Controlled Trial","VD-PD","Inclusion Criteria:\n\n* Medically stable and receiving peritoneal dialysis for \\> 1 month\n* Older than 18 years old\n* Serum 25(OH)D \\\u003C 30ng\u002Fml\n* Adequate dialysis on evaluation with weekly Kt\u002FV ≥ 1.5, or (revised time: 2023-7-11) without clinical uremic symptoms\n\nExclusion Criteria:\n\n* Receive Vitamin D2\u002FD3 during the previous 1 month (revised time: 2023-7-11) ;\n* History of allergic reaction to Cholecalciferol;\n* Current or past malignant disease, active hepatitis or hepatic failure, active autoimmune disease, severe digestive malabsorption or an eating disorder, HIV\u002FAIDS;\n* Acute systemic infection, cardiovascular disease, surgery, or trauma in the last month;\n* A high probability of receiving a kidney transplant or transferring to hemodialysis or drop-out due to socioeconomic causes within 6 months;\n* History of kidney transplant;\n* Hemodialysis combined with peritoneal dialysis currently;\n* Pregnant or breastfeeding;\n* Not suitable enrolled assessed by researchers, including patients who could not regular follow-up","19 Years",{"count":537,"type":21},176,[24],"This is a multicenter randomized, placebo-controlled trial of Vitamin D supplementation in patients on peritoneal dialysis to determine whether oral administration of vitamin D3 after curing an episode of peritonitis could reduce the risk of subsequent peritoneal dialysis-related peritonitis.",[541,29],"Peritoneal Dialysis-associated Peritonitis",[543,544,545],"Peritoneal dialysis","Peritonitis","Cholecalciferol","2024-08-05",{"date":548,"type":41},"2024-08-06",{"date":550,"type":41},"2023-06-15",{"date":552,"type":21},"2026-05-31",{"name":554,"class":48},"Peking University First Hospital",{"id":556,"slug":557,"hasResults":11,"nctId":558,"briefTitle":559,"officialTitle":560,"acronym":561,"eligibilityCriteria":562,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":563,"enrollmentInfo":564,"targetDuration":4,"studyType":22,"phases":566,"briefSummary":567,"conditions":568,"keywords":571,"overallStatus":143,"whyStopped":4,"lastUpdateSubmitDate":574,"lastUpdatePostDateStruct":575,"startDateStruct":577,"completionDateStruct":579,"leadSponsor":581,"locationsCount":4},"100535978","phase-4-restoration-of-vitamin-d-in-pulmonary-arterial-hypertension-100535978","NCT06258850","REstoration of VItamin D in Pulmonary Arterial Hypertension","REstoration With Calcifediol of VItamin D Deficiency in Pulmonary Arterial Hypertension Patients","REVIDAH","Inclusion Criteria:\n\n1. Male and female patients aged 18 -75 years.\n2. Patients with diagnosis of PAH of the following types according to 2022 ERS\u002FESC guidelines: idiopathic, hereditary, drug and toxin-induced PAH or associated to connective tissues disease.\n3. Patients who are stable and treated with standard medications for PAH on monotherapy or with combinations of drugs, including calcium channel blockers, phosphodiesterase type 5 inhibitors (PDE5i), endothelin receptor antagonists (ERA), prostacyclin analogues or selexipag or with stable dose of diuretics who had no treatment modification for at least 6 weeks before randomization.\n4. Patients with an intermediate-low and intermediate-high risk score according to 2022 ERS\u002FESC guidelines.\n5. Patients with severe deficiency of vitamin D, defined herein as plasma or serum 25(OH)vitamin D levels equal to or lower than 12 ng\u002Fml\n6. Patients who can understand and follow instructions, and who are able to participate in the study for the entire study.\n7. Patients must have given their written informed consent to participate in the study after having received adequate previous information and before any study-specific procedures.\n\nExclusion Criteria:\n\n1. Participation in another interventional clinical study within 30 days before screening.\n2. Previous randomisation to treatment during this study (no re-randomisation).\n3. Pregnant women or breastfeeding women, or women with childbearing potential not using a effective contraception method throughout the study.\n4. Patients with a medical disorder, condition, or history of such that would impair the patient's ability to participate in or complete this study, in the opinion of the investigator.\n5. Patients with substance abuse (eg, alcohol or drug abuse) within the previous 3 months before and at randomisation.\n6. Patients with underlying medical disorders with an anticipated life expectancy \\\u003C2 years.\n7. Patients with a history of severe allergies or multiple drug allergies or with hypersensitivity to the investigational drug or any of the excipients.\n8. Patients unable to perform a valid 6MWD test (eg, orthopaedic disease or peripheral artery occlusive disease that affects the patient's ability to walk).\n9. Excluded medication\u002Ftreatment: active treatment with digoxin.","75 Years",{"count":565,"type":21},102,[24],"Background. Pulmonary arterial hypertension (PAH) is a heterogeneous pathophysiological condition characterized by progressive pulmonary vascular narrowing that ultimately results in right-sided heart failure and eventually death or lung transplantation. The effectiveness of current pharmacological treatments is suboptimal and a large proportion of patients still had events or died despite receiving combination therapy. Vitamin D deficiency has been found to be much more frequent in PAH patients than in the general population or even compared to patients with other severe cardiovascular diseases. Moreover, vitamin D deficiency has a negative prognostic impact in PAH. Animal studies support that vitamin D deficiency worsens PAH.\n\nHypothesis. In patients with PAH and vitamin D deficiency, restoration of vitamin D status with calcifediol improves their symptomatology and prognosis.\n\nDesign: Multicenter clinical trial with the participation of 9 hospitals, placebo-controlled, randomized (1:1 ratio), in two parallel groups (without crossover), triple blind, and add-on on existing treatments (add-on). It will include at least 102 subjects (51 in the calcifediol group and 51 in the placebo group) followed for 24 weeks of treatment.\n\nInclusion criteria: Patients of both sexes (18-75 years) with hemodynamic diagnosis of PAH and severe vitamin D deficiency (25-OHvitD \\\u003C= 12 ng\u002Fml) and without previous diagnosis of osteoporosis or osteomalacia.\n\nTreatments: 1) Calcifediol Hydroferol® 0.266 mg once every 10 days for the first 12 weeks and once every two weeks for the following 12 weeks. 2) Placebo.\n\nMain objective: A composite endpoint of clinical improvement without clinical worsening at week 24.\n\nExpected outcome: Restoration of vitamin D status is an unexpensive measure, very easily implantable and that could improve the evolution of the disease as well as other aspects such as bone or immune health and that has few side effects.",[569,570],"Pulmonary Artery Hypertension","Vitamin d Deficiency",[572,573],"Clinical improvement","Clinical worsening","2024-02-06",{"date":576,"type":41},"2024-02-14",{"date":578,"type":21},"2024-07-01",{"date":580,"type":21},"2027-12",{"name":582,"class":48},"Parc de Salut Mar",{"id":584,"slug":585,"hasResults":11,"nctId":586,"briefTitle":587,"officialTitle":588,"acronym":589,"eligibilityCriteria":590,"healthyVolunteers":11,"sex":17,"minAge":257,"maxAge":591,"enrollmentInfo":592,"targetDuration":4,"studyType":22,"phases":594,"briefSummary":595,"conditions":596,"keywords":601,"overallStatus":143,"whyStopped":4,"lastUpdateSubmitDate":606,"lastUpdatePostDateStruct":607,"startDateStruct":609,"completionDateStruct":611,"leadSponsor":613,"locationsCount":49},"100531384","the-high-initial-dose-of-monitored-vitamin-d-supplementation-in-preterm-infants-100531384","NCT06199102","The High Initial Dose of Monitored Vitamin D Supplementation in Preterm Infants.","The High Initial Dose of Monitored Vitamin D Supplementation in Preterm Infants. A Randomized Controlled Study.","HIDVID","Inclusion Criteria:\n\n* preterm infants with a gestational age of 24+0\u002F7 to 32+6\u002F7 born at our clinic\n* preterm infants with a gestational age of 24+0\u002F7 to 32+6\u002F7 outborn and admitted to our intensive care unit within 48h after delivery\n* written informed consent form caregivers for the mother and the child to participate in the study\n\nExclusion Criteria:\n\n* infants born at \\>32 weeks of gestation\n* infants with major congenital abnormalities or other severe congenital malformations\n* infants with genetic disorders (diagnosed before and after birth) deemed incompatible with survival\n* infants with diagnosed cholestasis\n* the absence of written informed consent and challenges in communication with caregivers","2 Days",{"count":593,"type":21},130,[62],"The aim of this study will be to assess the effectiveness of monitored vit D supplementation in a population of preterm infants and to identify whether the proper vit D supplementation in preterm infants can reduce the incidence of neonatal sepsis and incidence of metabolic bone disease.",[29,597,598,599,600],"Osteopenia of Prematurity","Nephrolithiasis","Metabolic Bone Disease","Late-Onset Neonatal Sepsis",[312,602,603,604,605],"preterm infants","osteopenia of prematurity","late-onset sepsis","metabolic bone disease","2024-01-09",{"date":608,"type":41},"2024-01-10",{"date":610,"type":21},"2024-09-01",{"date":612,"type":21},"2027-12-31",{"name":614,"class":48},"Princess Anna Mazowiecka Hospital, Warsaw, Poland",{"id":616,"slug":617,"hasResults":11,"nctId":618,"briefTitle":619,"officialTitle":619,"acronym":4,"eligibilityCriteria":620,"healthyVolunteers":11,"sex":17,"minAge":257,"maxAge":389,"enrollmentInfo":621,"targetDuration":4,"studyType":92,"phases":4,"briefSummary":623,"conditions":624,"keywords":625,"overallStatus":143,"whyStopped":4,"lastUpdateSubmitDate":629,"lastUpdatePostDateStruct":630,"startDateStruct":632,"completionDateStruct":634,"leadSponsor":636,"locationsCount":49},"100524617","vitamin-d-levels-in-neonatal-umbilical-cord-blood-factors-and-prognostic-analysis-100524617","NCT06111066","Vitamin D Levels in Neonatal Umbilical Cord Blood: Factors and Prognostic Analysis","Inclusion Criteria:\n\n* Newborns delivered in Sun Yat-sen Memorial Hospital's obstetrics department.\n* Relatives agree to use clinically discarded specimens for research and have signed a consent form.\n\nExclusion Criteria:\n\n* Newborns with genetic mutations or congenital malformations.\n* Patients who died before discharge.\n* Pregnant women with conditions like chylous diarrhea, inflammatory bowel disease, and other chronic digestive system diseases.",{"count":622,"type":21},186,"This study is a retrospective-prospective cohort study that investigates the factors influencing neonatal umbilical cord blood 25(OH)D levels, and the impact of exposure to low intrauterine 25(OH)D levels on neonatal prognosis. Newborns born in Sun Yat-sen Memorial Hospital of Sun Yat-sen University from August 2023 to August 2024 were selected. 2ml of umbilical cord blood was collected to test serum 25(OH)D levels. Based on the umbilical cord blood 25(OH)D levels, newborns were divided into three groups: vitamin D deficiency (\\\u003C30nmol\u002FL), insufficiency (30\\~50nmol\u002FL), and sufficiency (\\>50\\~250nmol\u002FL). Factors influencing neonatal vitamin D levels at birth were investigated by reviewing medical records, questionnaire collection, phone interviews, etc., collecting data on basic neonatal information, maternal information, complications during pregnancy, prenatal biochemical test results, medication history during pregnancy, lifestyle habits during pregnancy, and vitamin D supplementation status. Phone follow-ups on the health of the newborns during their hospital stay and at 1 month and 2 months after discharge were conducted to investigate the impact of exposure to low intrauterine 25(OH)D levels on neonatal prognosis, providing a theoretical basis for early intervention in high-risk pregnant women and early identification of high-risk groups with vitamin D deficiency or insufficiency among newborns.\n\nMiscarriages prevention is a major feature of our hospital's obstetrics department. Many pregnant women who are hospitalized and give birth at our hospital have a history of fetus protection. Choosing pregnant women and newborns from our hospital's obstetrics department as research subjects is conducive to exploring the impact of specific diseases and medication histories on neonatal vitamin D deficiency, which is an innovative aspect of this study.",[570],[312,626,627,628],"neonatal umbilical cord blood","influence factors","prognosis","2023-10-26",{"date":631,"type":41},"2023-11-01",{"date":633,"type":21},"2024-01-01",{"date":635,"type":21},"2029-12-30",{"name":637,"class":48},"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University",{"id":639,"slug":640,"hasResults":11,"nctId":641,"briefTitle":642,"officialTitle":642,"acronym":4,"eligibilityCriteria":643,"healthyVolunteers":57,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":644,"targetDuration":4,"studyType":22,"phases":645,"briefSummary":646,"conditions":647,"keywords":4,"overallStatus":143,"whyStopped":4,"lastUpdateSubmitDate":652,"lastUpdatePostDateStruct":653,"startDateStruct":655,"completionDateStruct":657,"leadSponsor":659,"locationsCount":4},"100464041","meniers-disease---bone-density-study-100464041","NCT05322538","Menier's Disease - Bone Density Study","Inclusion Criteria:\n\n* Definite Meniere's disease\n\nExclusion Criteria:\n\n* hyperthyroidism\n* hyperparathyroidism\n* acromegaly\n* hypogonadism\n* diabetes melitus\n* chronic renal failure\n* alcoholism\n* cushing syndrome\n* rheumatoid arthritis\n* systemic lupus erythematosus\n* ankylosing spondylitis\n* inflammatory bowel disease\n* obstructive lung disease\n* sarcoidosis\n* amyloidosis\n* celiac disease.\n* chronic treatment with bisphosphonates\n* chronic treatment with glucocorticoids\n* chronic treatment with androgen deprivation therapy\n* chronic treatment with gonadotropin releasing hormone agonist chronic treatment with aromatase inhibitor chronic treatment with loop diuretics chronic treatment with proton pump inhibitors chronic treatment with anti-seizure drugs chronic treatment with warfarin chronic treatment with SSRI chronic treatment with alpha or beta-blockers",{"count":209,"type":21},[62],"Meniere's disease is a progressive and debilitating inner ear disease characterised by vertigo and hearing loss. Several studies have linked Menierws disease with lower bone density and lower vitamin D levels. In the current prospective study definite Meniere's patients will be followed over a period of 2 year, during which repetitive measurements of bone density, vitamin D plasma levels, blood pressure as well as hearing and vestibular tests will be made. Results will be compared to healthy controls.",[648,649,650,29,651],"Meniere Disease","Osteoporosis","Osteopenia","Vestibular Disorder","2022-08-02",{"date":654,"type":41},"2022-08-03",{"date":656,"type":21},"2022-10-01",{"date":658,"type":21},"2028-12-31",{"name":660,"class":48},"HaEmek Medical Center, Israel"]